Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) EBITDA: 2009-2024

Historic EBITDA for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$57.2 million.

  • Anika Therapeutics' EBITDA rose 91.39% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.3 million, marking a year-over-year increase of 66.61%. This contributed to the annual value of -$57.2 million for FY2024, which is 30.36% up from last year.
  • As of FY2024, Anika Therapeutics' EBITDA stood at -$57.2 million, which was up 30.36% from -$82.2 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' EBITDA ranged from a high of $3.0 million in FY2021 and a low of -$82.2 million during FY2023.
  • In the last 3 years, Anika Therapeutics' EBITDA had a median value of -$57.2 million in 2024 and averaged -$51.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 113.07% in 2021, then tumbled by 626.84% in 2022.
  • Anika Therapeutics' EBITDA (Yearly) stood at -$22.6 million in 2020, then soared by 113.07% to $3.0 million in 2021, then tumbled by 626.84% to -$15.6 million in 2022, then tumbled by 427.25% to -$82.2 million in 2023, then soared by 30.36% to -$57.2 million in 2024.